{
    "nct_id": "NCT05628597",
    "official_title": "Effects of the Fos Biomedical Device on Diabetes Risk Factors and Sleep Quality in Adults at Risk for Type 2 Diabetes: A Randomized, Placebo-controlled, Crossover Trial",
    "inclusion_criteria": "(1) Males > 40 years of age; (2) Post-menopausal females not currently on hormone replacement therapy; (3) Non-smokers; (4) Overweight with BMI ≥25kg/m²; (5) At risk for type 2 diabetes as defined by meeting at least one of the criteria listed below: (i) Metabolic syndrome, i.e. meet three out of five of the following criteria:\n\n1. Blood pressure >130/85 mmHg or currently taking antihypertensive medication;\n2. Fasting plasma glucose (FPG) >100 mg/dL (6.1 mmol/L);\n3. Serum triglycerides level (TG)>150 mg/dL (1.69 mmol/L);\n4. High-density lipoprotein (HDL) cholesterol level < 40 mg/dL (1.04 mmol/L) in men, and < 50 mg/dL (1.29 mmol/L) in women;\n5. Waist circumference of >40 inches (102 cm) for men and > 35 inches (88 cm) for women; fasting blood glucose >100mg/dL and <126mg/dL.\n\n(ii) Hemoglobin A1C in the range of 5.7-6.4%\nHealthy volunteers allowed\nMust have minimum age of 40 Years",
    "exclusion_criteria": "1. Failure to meet inclusion criteria;\n2. Anticipated inability to complete study protocol for any reason;\n3. Type 1 or type 2 diabetes;\n4. Personal history or family history of skin cancer;\n5. Having lupus;\n6. Having liver disease;\n7. Use of lipid-lowering or antihypertensive medications, unless stable on medication for at least 3 months and willing to refrain from taking medication for 12 hours prior to clinical outcome measures assessment;\n8. Regular use of high doses of vitamin E or C;\n9. Use of insulin, glucose-sensitizing medication, vasoactive medication (including glucocorticoids, antineoplastic agents, psychoactive agents, or bronchodilators) or nutraceuticals;\n10. Regular use of fiber supplements;\n11. Sleep apnea;\n12. Coagulopathy, known bleeding diathesis, or history of clinically significant hemorrhage; or current use of warfarin.\n13. Known allergic or dermatological reactions to any of the components of the patch product or placebo - polyethylene, silicone, or acrylate adhesive - that could have contact with the skin of study participants during their use of the product.",
    "miscellaneous_criteria": ""
}